The equine health market size was valued at USD 2.14 billion in 2024 and is expected to reach USD 3.69 billion by 2032, growing at a CAGR of 7.08% over 2025-2032.
The equine health market is doing well, driven by greater expenditure on the latest diagnostics, novel therapeutic options, and a spurt in equine wellness awareness. Bringing sophisticated technology, such as the ASTO CT Equina standing CT scanner from Equine Innovative Medicine, allows better image quality earlier in the disease process and makes safer procedures possible.
In June 2025, PetVivo Holdings entered into a partnership with Commonwealth Thoroughbred to advance equine health with its regenerative therapeutic, Spryng, illustrating a growing trend towards biotech treatments.
Partnerships such as Boehringer Ingelheim and Sleip’s AI motion analysis platform are changing performance diagnostics. Increasing incidents of infectious diseases such as Eastern Equine Encephalitis (EEE) are being reported by the CDC and by Merck’s biosurveillance system, increasing the need for vaccines and quick testing. Regulatory harmonization through the World Organisation for Animal Health (WOAH) is facilitating international equine transport, leading to increased global competition and commerce. Rising numbers of pet insurance policies and vet visits, according to AAHA and YourHorse, also indicate increased owner investment in their horses' healthcare. Both academic and private R&D investment, including Massey University’s equine health-endowed chair and the growth and development of biosurveillance networks, also demonstrate a commitment to innovation.
In April 2024, Boehringer Ingelheim and Sleip have brought motion analysis with artificial intelligence to detect lameness early in equines with the next generation of equine precision health tools.
Market Dynamics:
Drivers:
Rising Demand for Preventive Care, Increasing Awareness About Animal Health, and Technological Innovations Fuel Market Growth
Annual equine checkups have also been increasing, overall, up 10% in the last three years, the AAHA said, as a greater number of competitive and recreational riders have beefed up ownership. Organizations, such as Merck Animal Health, have bolstered their biosurveillance capabilities to improve the detection of disease and planning of vaccines. Regulatory changes, such as the U.S. Department of Agriculture (USDA) equine disease reporting systems, have improved disease response. It is also worth noting that a lot of money is being poured into diagnostics innovation (as we can tell from the market for equine-specific imaging tools and wearables for monitoring devices in the U.S. CA Diagnostics market).
R&D expenditure is also growing, as evidenced by the introduction of a performance-enhancing equine range by Poseidon Animal Health into the U.S. market in 2024 after extensive research-led product creation. Merck’s partnership with the U.S. Trotting Association, meanwhile, topped the toga as events go, bringing a leap forward in horse care innovation through API-based monitoring performance markers. This coordinated public-private effort is representative of the market’s rapid shift towards high-tech, data-driven, and wellness-biased equine healthcare products and services.
Restraints:
The Primary Limitations Hindering the Growth of the Equine Health Market, Especially in Terms of Access, Cost, and Infrastructure
One critical barrier is the associated cost of more advanced diagnostics and treatments, which restricts access for smaller farms and rural horse owners. Revolutionary devices like the ASTO CT Equina scanner, which does not scale as it requires significant upfront infrastructure and investment, limit the potential user base. Furthermore, equine insurance coverage is patchy and restricted, and a YourHorse feature explained that less than 40% of horse owners in both the U.K. and the U.S. have policies that fully insure their animals for chronic conditions or any surgeries they may require.
Access to veterinary care in rural or under-resourced regions exacerbates the problem, with research demonstrating that its availability among geographical regions varies in regards to uptake of preventative care. Regulatory deficiencies remain an issue, too, although there have been improvements to international horse-movement standards, vaccine guidelines and approval pathways remain disjointed and too slow in delivering critical therapeutics in some places. In addition, sources of plaque, from fomites to dowel rods, for heightened bird concentrations had some impact, but this effort tends to be more reactive, such as in response to West Nile Virus or Western Equine Encephalitis, versus proactive design and planning.
Disjointed distribution and differences in electronic health records further present hurdles to evidence-based treatment progress. Such limitations reveal the requirements of broader policies and of technologies that can be scaled.
By Product
The drug class category remained the largest segment, with a market share of 48.9% in 2024, as the class of anti-inflammatory, antiparasitic, and antibiotic drugs is in frequent use for the treatment of common diseases of lameness, infections, and respiratory diseases. This perspective is reinforced by the proximate status of these drugs in both the performance and recreational management of horses.
Vaccines are expected to be the fastest-growing, with the increasing incidence of infectious diseases, such as West Nile and Equine Herpes Virus. Growing legislative encouragement for prophylaxis therapy, such as the USDA vaccination protocol, and increased owner consciousness after the pandemic are causing vaccination rates to increase.
By Disease Type
The “others” segment was the segment with the largest market share in 2024, accounting for almost 30% of overall market revenues, since it includes a variety of metabolic, gastrointestinal, and musculoskeletal diseases commonly treated in the equine population. However, the West Nile Virus is expected to be the fastest growing segment due to an increase in the reported cases and implementation of proactive biosurveillance. The Merck Equine Disease Outbreak Map continues to illustrate a steady increase in reported cases throughout North America, further fueling the need for targeted vaccines and early diagnostic tools.
By Distribution Channel
Veterinary hospitals and clinics dominated the market in 2024, and contributed over 54% of the market share, as they are pivoting their facilities to provide treatments, diagnostics, and surgical procedures. They deliver the primary care for horses, both emergency and routine. In the meantime, retail pharmacies and drug stores will continue to be the fastest-growing market, driven by growing owner preference for OTC supplements, dewormers, and preventives. The increasing availability of online veterinary pharmacies and horses’ easy access to licensed equine drugs also play a role in the continued expansion of this channel.
North America was the largest equine health market in 2024, driven by a large equine-based population, developed veterinary facilities, and a greater number of research and development activities in the field of veterinary healthcare. The U.S. equine health market size was valued at USD 0.77 billion in 2024 and is expected to reach USD 1.23 billion by 2032, growing at a CAGR of 6.15% over 2025-2032. The U.S. dominates, followed by more than 60% regional share, as there is a large-scale utilization of advanced diagnostics, vaccines, and a favorable regulatory environment. Canada is the fastest-growing country due to a rise in consciousness of equine wellbeing, and government disease rationales. Mexico boasts consistent growth driven by growth in equestrian disciplines and ownership of horses. Growth of the region can also be attributed to increasing demand for preventive care and technological advancements in equine health management.
The Asia Pacific region is expanding at a fast pace on the back of the growing popularity of equestrian sports and increasing middle-class prosperity, and the government supports animal health programs. Japan has the most developed horse industry and best veterinary care, and it is also the largest market, whereas China is the fastest growing, owing to increased horse ownership and promotional campaigns. India and Australia are also responsible for the occurrence due to the developing equestrian tourism and racing industry. The growth in the region will be driven by enhanced veterinary infrastructure in the region and growing spending on animal health.
Europe’s market expansion is facilitated by a rich equine heritage, advanced veterinary services, and strict governance requirements for animal welfare and drug clearance. Germany leads with approximately 25% of the regional share as a result of its pharmaceutical acumen and animal welfare legislation. The U.K. is the fastest-growing country, with increasing demand for preventive care and increasing penetration of equine insurance. Other countries, such as France and Italy, are also promoting growth by developing animal sports. The growth in the region is driven by higher R&D funding and a similar regulatory environment for product launches.
Major equine health companies operating in the market are Zoetis Services LLC, Ceva, Elanco, Boehringer Ingelheim, Vetoquinol, Neogen Corporation, Virbac, Merck & Co., Norbrook, Purina Animal Nutrition LLC, Kyoritsuseiyaku Corporation, and Equine Products UK Ltd.
In February 2025, the New Zealand Equine Trust funded a 10-year Chair position in Equine Health, Welfare, and Performance at Massey University's Tāwharau Ora School of Veterinary Science. Professor Chris Rogers was appointed to this role, aiming to advance research in equine health and welfare and to strengthen New Zealand's reputation as a leader in equine science.
In Q3 2025, PetVivo Holdings, Inc. reported significant progress in expanding its distribution network for its flagship product, Spryng with OsteoCushion Technology. The company announced new distribution partnerships with Vedco and Clipper Distributing, which supply major national veterinary product distributors in the U.S.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 2.14 billion |
| Market Size by 2032 | USD 3.69 billion |
| CAGR | CAGR of 7.08% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Drug Class (Anti-Infective, Anti-Inflammatory, Parasiticides, and Others), Vaccines (Inactivated, Live Attenuated, Recombinant, and Others), and Supplemental Feed Additives • By Disease Type (West Nile Virus, Equine Rabies, Equine Influenza, Equine Herpes Virus, Potomac Horse Fever, Tetanus, and Others) • By Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies and Drug Stores, and Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Zoetis Services LLC, Ceva, Elanco, Boehringer Ingelheim, Vetoquinol, Neogen Corporation, Virbac, Merck & Co., Norbrook, Purina Animal Nutrition LLC, Kyoritsuseiyaku Corporation, and Equine Products UK Ltd. |
Ans: The Equine Health Market is projected to grow at a CAGR of 7.08% during the forecast period.
Ans: By 2032, the Equine Health Market is expected to reach USD 3.69 billion, up from USD 2.14 billion in 2024.
Ans: Rising demand for preventive care, increasing awareness about animal health, and technological innovations fuel market growth.
Ans: The primary limitations hindering the growth of the equine health market, especially in terms of access, cost, and infrastructure.
Ans: North America is the dominant region in the equine health market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Equine Population and Disease Prevalence (2024)
5.2 Veterinary Care Utilization & Treatment Trends (2024), by Region
5.3 Equine Health Product Consumption (2021–2032), by Region
5.4 Equine Healthcare Expenditure, by Region (2024)
5.5 Equine Insurance Penetration and Claims Trends (2024)
5.6 Equine Wellness and Preventive Care Adoption Rates (2024)
5.7 Research & Development Activity and Clinical Trials (2024)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Equine Health Market Segmentation by Product
7.1 Chapter Overview
7.2 Drug Class
7.2.1 Drug Class Market Trends Analysis (2021-2032)
7.2.2 Drug Class Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Anti-Infective
7.2.3.1 Anti-Infective Market Trends Analysis (2021-2032)
7.2.3.2 Anti-Infective Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Anti-Inflammatory
7.2.4.1 Anti-Inflammatory Market Trends Analysis (2021-2032)
7.2.4.2 Anti-Inflammatory Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Parasiticides
7.2.5.1 Parasiticides Market Trends Analysis (2021-2032)
7.2.5.2 Parasiticides Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.6 Others
7.2.6.1 Others Market Trends Analysis (2021-2032)
7.2.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Vaccines
7.3.1 Vaccines Market Trends Analysis (2021-2032)
7.3.2 Vaccines Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Inactivated
7.3.3.1 Inactivated Market Trends Analysis (2021-2032)
7.3.3.2 Inactivated Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Live Attenuated
7.3.4.1 Live Attenuated Market Trends Analysis (2021-2032)
7.3.4.2 Live Attenuated Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Recombinant
7.3.5.1 Recombinant Market Trends Analysis (2021-2032)
7.3.5.2 Recombinant Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.6 Others
7.3.6.1 Others Market Trends Analysis (2021-2032)
7.3.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Supplemental Feed Additives
7.4.1 Supplemental Feed Additives Market Trends Analysis (2021-2032)
7.4.2 Supplemental Feed Additives Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Equine Health Market Segmentation By Disease Type
8.1 Chapter Overview
8.2 West Nile Virus
8.2.1 West Nile Virus Market Trend Analysis (2021-2032)
8.2.2 West Nile Virus Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Equine Rabies
8.3.1 Equine Rabies Market Trends Analysis (2021-2032)
8.3.2 Equine Rabies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Equine Influenza
8.4.1 Equine Influenza Market Trends Analysis (2021-2032)
8.4.2 Equine Influenza Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Equine Herpes Virus
8.5.1 Equine Herpes Virus Market Trends Analysis (2021-2032)
8.5.2 Equine Herpes Virus Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Potomac Horse Fever
8.6.1 Potomac Horse Fever Market Trends Analysis (2021-2032)
8.6.2 Potomac Horse Fever Market Size Estimates and Forecasts to 2032 (USD Billion)
8.7 Tetanus
8.7.1 Tetanus Market Trends Analysis (2021-2032)
8.7.2 Tetanus Market Size Estimates and Forecasts to 2032 (USD Billion)
8.8 Others
8.8.1 Others Market Trends Analysis (2021-2032)
8.8.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Equine Health Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Veterinary Hospitals and Clinics
9.2.1 Veterinary Hospitals and Clinics Market Trends Analysis (2021-2032)
9.2.2 Veterinary Hospitals and Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies and Drug Stores
9.3.1 Retail Pharmacies and Drug Stores Market Trends Analysis (2021-2032)
9.3.2 Retail Pharmacies and Drug Stores Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2021-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Equine Health Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.4 North America Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.2.5 North America Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.6.2 USA Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.2.6.3 USA Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.7.2 Canada Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.2.7.3 Canada Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.2.8.2 Mexico Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.2.8.3 Mexico Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Equine Health Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.4 Europe Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.5 Europe Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.1.6.1 Germany Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.1.6.2 Germany Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.1.6.3 Germany Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.7.2 France Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.7.3 France Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.8.2 UK Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.8.3 UK Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.9.2 Italy Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.9.3 Italy Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.10.2 Spain Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.10.3 Spain Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Poland
10.3.12.1 Poland Equine Health Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.12.1 Poland Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.12.3 Poland Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.12.3 Poland Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Turkey
10.3.13.1 Turkey Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.13.2 Turkey Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.13.3 Turkey Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.14 Rest of Europe
10.3.14.1 Rest of Europe Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.3.14.2 Rest of Europe Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.3.14.3 Rest of Europe Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia-Pacific
10.4.1 Trends Analysis
10.4.2 Asia-Pacific Equine Health Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia-Pacific Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.4 Asia-Pacific Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.5 Asia-Pacific Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.6.2 China Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.6.3 China Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.7.2 India Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.7.3 India Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.8.2 Japan Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.8.3 Japan Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.9.2 South Korea Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.9.3 South Korea Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.10.2 Singapore Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.10.3 Singapore Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.11.2 Australia Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.11.3 Australia Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia-Pacific
10.4.12.1 Rest of Asia-Pacific Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia-Pacific Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia-Pacific Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa East Equine Health Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.6.2 UAE Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.5.6.3 UAE Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Qatar
10.5.8.1 Qatar Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.8.2 Qatar Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.5.8.3 Qatar Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 South Africa
10.5.9 1 South Africa Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.9 2 South Africa Equine Health Market Estimates and Forecasts By Disease Type (2021-2032) (USD Billion)
10.5.9 3 South Africa Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 Rest of Middle East & Africa
10.5.10.1 Rest of Middle East & Africa Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.5.10.2 Rest of Middle East & Africa Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.5.10.3 Rest of Middle East & Africa Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Equine Health Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.4 Latin America Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.6.5 Latin America Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.6.2 Brazil Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.6.6.3 Brazil Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.7.2 Argentina Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.6.7.3 Argentina Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Equine Health Market Estimates and Forecasts, by Product (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Equine Health Market Estimates and Forecasts, By Disease Type (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Equine Health Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
12. Company Profiles
12.1 Zoetis Services LLC
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Ceva
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Elanco
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 Boehringer Ingelheim
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Vetoquinol
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Neogen Corporation
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Virbac
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Merck & Co.
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Purina Animal Nutrition LLC
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Equine Products UK Ltd
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Drug Class
Anti-Infective
Anti-Inflammatory
Parasiticides
Others
Vaccines
Inactivated
Live Attenuated
Recombinant
Others
Supplemental Feed Additives
By Disease Type
West Nile Virus
Equine Rabies
Equine Influenza
Equine Herpes Virus
Potomac Horse Fever
Tetanus
Others
By Distribution Channel
Veterinary Hospitals and Clinics
Retail Pharmacies and Drug Stores
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g., Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players